{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:20:02Z","timestamp":1781821202783,"version":"3.54.5"},"reference-count":29,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,3,31]]},"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>A woman in her 50s previously treated for early-stage breast cancer, parotid mucoepidermoid carcinoma and Caroli\u2019s disease was diagnosed with stage IV pancreatic ductal adenocarcinoma (PDAC) metastatic to the liver and was found to harbour a <jats:italic>BRCA1<\/jats:italic> germline mutation. She had palliative chemotherapy, initially with 5-fluorouracil, leucovorin, irinotecan and oxaliplatin, and then FOLFIRI and capecitabine, achieving a sustained near-complete response for at least 86 months. Chemotherapy was eventually discontinued when she was diagnosed with a tongue squamous cell carcinoma. Despite withholding systemic therapy, she has maintained a durable response. This is the first report in the English literature showing a sustained duration of response in a patient with PDAC and BRCA<jats:italic>1<\/jats:italic> germline mutation.<\/jats:p>","DOI":"10.1136\/bcr-2022-249370","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T11:58:36Z","timestamp":1651233516000},"page":"e249370","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Response in <i>BRCA1<\/i> mutation carrier with metastatic pancreatic adenocarcinoma treated with FOLFIRINOX"],"prefix":"10.1136","volume":"15","author":[{"given":"Leticia Estefania","family":"Campoverde","sequence":"first","affiliation":[{"name":"Internal Medicine, University of Miami Health System, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Batalini","sequence":"additional","affiliation":[{"name":"Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarab","family":"Bulushi","sequence":"additional","affiliation":[{"name":"Radiology, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bullock","sequence":"additional","affiliation":[{"name":"Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"key":"2025082707514948000_15.4.e249370.1","unstructured":"National Cancer Institute . Pancreatic cancer \u2014 cancer Stat facts. Available: https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html [Accessed 18 Dec 2020]."},{"key":"2025082707514948000_15.4.e249370.2","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.20.01364","article-title":"Metastatic pancreatic cancer: ASCO guideline update","volume":"38","author":"Sohal","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025082707514948000_15.4.e249370.3","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1166"},{"key":"2025082707514948000_15.4.e249370.4","doi-asserted-by":"crossref","unstructured":"Conroy T , Ychou M , Bouch\u00e9 O . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer 2011.","DOI":"10.4267\/2042\/45859"},{"key":"2025082707514948000_15.4.e249370.5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29664"},{"key":"2025082707514948000_15.4.e249370.6","doi-asserted-by":"publisher","DOI":"10.1002\/mc.20855"},{"key":"2025082707514948000_15.4.e249370.7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i31.10778"},{"key":"2025082707514948000_15.4.e249370.8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.15.1310"},{"key":"2025082707514948000_15.4.e249370.9","first-page":"1365","article-title":"Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program","volume":"94","author":"Brose","year":"2002","journal-title":"CancerSpectrum Knowl Environ"},{"key":"2025082707514948000_15.4.e249370.10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206177"},{"key":"2025082707514948000_15.4.e249370.11","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.418"},{"key":"2025082707514948000_15.4.e249370.12","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/jjco\/hyz141","article-title":"Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report","volume":"49","author":"Shimmura","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"2025082707514948000_15.4.e249370.13","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.12.3.16292"},{"key":"2025082707514948000_15.4.e249370.14","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3390\/genes11121451","article-title":"Five Italian Families with Two Mutations in BRCA Genes","volume":"11","author":"Vietri","year":"2020","journal-title":"Genes"},{"key":"2025082707514948000_15.4.e249370.15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/SLA.0000000000002672","article-title":"Is a pathological complete response following neoadjuvant chemoradiation associated with prolonged survival in patients with pancreatic cancer?","volume":"268","author":"He","year":"2018","journal-title":"Ann Surg"},{"key":"2025082707514948000_15.4.e249370.16","doi-asserted-by":"publisher","DOI":"10.1038\/nature24477"},{"key":"2025082707514948000_15.4.e249370.17","doi-asserted-by":"crossref","unstructured":"Sessa G , G\u00f3mez\u2010Gonz\u00e1lez B , Silva S . BRCA2 promotes R\u2010loop resolution by DDX5 helicase at DNA breaks to facilitate their repair by homologous recombination. EMBO J 2021:e106018.","DOI":"10.15252\/embj.2020106018"},{"key":"2025082707514948000_15.4.e249370.18","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016600","article-title":"Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins","volume":"7","author":"Prakash","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2025082707514948000_15.4.e249370.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(01)00175-7"},{"key":"2025082707514948000_15.4.e249370.20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3747\/co.v18i1.708","article-title":"Oxaliplatin: a review in the era of molecularly targeted therapy","volume":"18","author":"Alcindor","year":"2011","journal-title":"Current Oncology"},{"key":"2025082707514948000_15.4.e249370.21","unstructured":"Bolton KL , Chenevix-Trench G , Goh C . Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. Available: https:\/\/jamanetwork.com\/"},{"key":"2025082707514948000_15.4.e249370.22","unstructured":"Boyd J , Sonoda Y , Federici MG . Clinicopathologic features of BRCA-Linked and sporadic ovarian cancer. Available: https:\/\/jamanetwork.com\/ [Accessed 7 Mar 2021]."},{"key":"2025082707514948000_15.4.e249370.23","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3100-x"},{"key":"2025082707514948000_15.4.e249370.24","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.19.03292","article-title":"TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial)","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025082707514948000_15.4.e249370.25","doi-asserted-by":"crossref","unstructured":"Wattenberg MM , Asch D , Yu S . Article platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.doi:10.1038\/s41416-019-0582-7","DOI":"10.1038\/s41416-019-0582-7"},{"key":"2025082707514948000_15.4.e249370.26","doi-asserted-by":"crossref","first-page":"11637","DOI":"10.2147\/OTT.S276814","article-title":"Clinical Characteristics and Prognosis of Gastric Cancer Patients with BRCA 1\/2 Germline Mutations: Report of Ten Cases and a Literature Review","volume":"13","author":"Halpern","year":"2020","journal-title":"Onco Targets Ther"},{"key":"2025082707514948000_15.4.e249370.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903387"},{"key":"2025082707514948000_15.4.e249370.28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.6004\/jnccn.2020.0017","article-title":"Genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020 featured updates to the NCCN guidelines","volume":"18","author":"Daly","year":"2020","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"key":"2025082707514948000_15.4.e249370.29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01489"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-249370","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:52:02Z","timestamp":1756306322000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-249370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,29]]},"published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1136\/bcr-2022-249370"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-249370","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}